<DOC>
	<DOCNO>NCT02815137</DOCNO>
	<brief_summary>The purpose study determine XPO1 E571K mutation could use molecular residual disease biomarker classical Hodgkin 's lymphoma . To determine interest mutation assessment digital Polymerase Chain Reaction , sensitivity specificity 2 course chemotherapy ( C2 ) compare deltaSUVmax determine Positron Emission Tomography C2 end treatment .</brief_summary>
	<brief_title>Detection Prognostic Value Recurrent XPO1 Mutations Patients With Classical Hodgkin Lymphoma</brief_title>
	<detailed_description>A research team Centre Henri Becquerel recently detect unexpected recurrent point mutation XPO1 ( exportin 1 ) ( also know Chromosome Region Maintenance 1 ) locate exon 15 ( c.1711G &gt; A ) lead Glu571Lys ( p.E571K ) missense substitution relapsed/refractory ( R/R ) Primary Mediastinal Large B-cell Lymphoma ( PMBL ) patient include LYSA LNH03 trial program classical Hodgkin 's Lymphoma patient . It find recurrent XPO1 E571K mutation large cohort 94 patient classical Hodgkin 's lymphoma . This observation new could add new information driver event tumorigenesis disease . In total , 24.2 % patient classical Hodgkin 's lymphoma harbor XPO1 E571K mutation . It remarkable 29 % XPO1 mutation find plasma tumor well-known tumor cell sparsity Hodgkin 's lymphoma . In particular disease , highly sensitive technique like digital Polymerase Chain Reaction target Next-Generation Sequencing essential highlight low frequency mutation . The research team Centre Henri Becquerel identify trend toward unfavorable prognostic impact term progression-free survival patient detectable XPO1 E571K mutation plasma cell-free DNA end treatment , could prove statistically significant large cohort . It observe 57 % patient ultimately relapse positive plasma end therapy . It remain establish whether mutation add new relevant value compare Positron Emission Tomography-scan .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Age â‰¥18 year Pathologically confirm , recent diagnosis classical Hodgkin Lymphoma treatment plan Adriamycin Bleamycin Vinblastine Dacarbazine ( ABVD ) Bleomycin Etoposide Adriamycin Cyclophosphamide Vincristine Procarbazine Prednisone ( BEACOPP ) regimen ( radiotherapy applicable ) stage ( Ann Arbor I IV ) Written informed consent Patient affiliate beneficiary benefit system untreated patient ( corticosteroid chemotherapy ) No informed consent Treatment ABVD BEACOPP indicate Previously treat Hodgkin lymphoma ( include corticosteroid ) Patients pregnant lactate Active Hepatitis B Hepatitis C infection Known human immunodeficiency virus ( HIV ) infection Patient social protection Patient tutorship curatorship Patient affiliate beneficiary benefit system Medical contraindication PET/CT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Digital PCR</keyword>
	<keyword>classical</keyword>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>mutation</keyword>
</DOC>